AstraZeneca Looks to Replenish Late-Stage Pipeline with US$1.26 B Ardea Biosciences Acquisition
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 4 (Table of Contents)
Published: 30 Apr-2012
DOI: 10.3833/pdr.v2012.i4.1733 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
AstraZeneca has agreed to acquire Ardea Biosciences for US$32 per share, which represents a 54% premium over the company’s closing price prior to the announcement of the transaction and equates to a total cash value of US$1...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS